Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 16:15:1376955.
doi: 10.3389/fphar.2024.1376955. eCollection 2024.

The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment

Yuanyuan Liu  1 , Shanwu Yu  2 , Yixiang Chen  3 , Zhihong Hu  1 , Lingling Fan  1 , Gaofeng Liang  1
Affiliations
Review

The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment

Yuanyuan Liu et al. Front Pharmacol. .

Abstract

Hematologic malignancies (HMs), also referred to as hematological or blood cancers, pose significant threats to patients as they impact the blood, bone marrow, and lymphatic system. Despite significant clinical strategies using chemotherapy, radiotherapy, stem cell transplantation, targeted molecular therapy, or immunotherapy, the five-year overall survival of patients with HMs is still low. Fortunately, recent studies demonstrate that the nanodrug delivery system holds the potential to address these challenges and foster effective anti-HMs with precise treatment. In particular, cell membrane camouflaged nanodrug offers enhanced drug targeting, reduced toxicity and side effects, and/or improved immune response to HMs. This review firstly introduces the merits and demerits of clinical strategies in HMs treatment, and then summarizes the types, advantages, and disadvantages of current nanocarriers helping drug delivery in HMs treatment. Furthermore, the types, functions, and mechanisms of cell membrane fragments that help nanodrugs specifically targeted to and accumulate in HM lesions are introduced in detail. Finally, suggestions are given about their clinical translation and future designs on the surface of nanodrugs with multiple functions to improve therapeutic efficiency for cancers.

Keywords: cell membrane camouflage; clinical regimens; hematologic malignancies; nanocarrier; nanodrug delivery system.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Schematic of the pathological differentiation of lymphoma (A), leukemia (B) and MM (C), copy from (Powsner et al., 2021) with license under CC BY 4.0.
FIGURE 2
FIGURE 2
The scheme of HSCT for HMs patient. Created by BioRender (agreement number: NT26D16T7T).
FIGURE 3
FIGURE 3
The processes of preparing CAR-immune cell. Created by BioRender (agreement number: TS26D15BJS).
FIGURE 4
FIGURE 4
The common nanocarriers for drug delivery in HMs treatment. Created by BioRender (agreement number: TS26D15BJS).
FIGURE 5
FIGURE 5
The main types of cell membrane and membrane proteins used for camouflaging nanodrug in HMs treatment. Created by BioRender (agreement number: NT26D16T7T).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Abuasab T., Garcia-Manero G., Short N., Alvarado Y., Issa G. C., Islam R., et al. (2022). Phase 2 study of ASTX727 (cedazuridine/decitabine) plus venetoclax in patients with relapsed/refractory acute myeloid leukemia (AML) or previously untreated, elderly patients with AML unfit for chemotherapy. Blood 140 (Suppl. 1), 3324–3326. 10.1182/blood-2022-158566 - DOI
    1. Adamo F. M., Silva Barcelos E. C., De Falco F., Dorillo E., Rompietti C., Sorcini D., et al. (2023). Therapeutic targeting potential of novel silver nanoparticles coated with anti-CD20 antibody against chronic lymphocytic leukemia. Cancers 15 (14), 3618. 10.3390/cancers15143618 - DOI - PMC - PubMed
    1. Ahmad E., Ali A., Fatima M. T., Kumar A., Sumi M. P., Sattar R. S. A., et al. (2021). Ligand decorated biodegradable nanomedicine in the treatment of cancer. Pharmacol. Res. 167, 105544. 10.1016/j.phrs.2021.105544 - DOI - PubMed
    1. Alaggio R., Amador C., Anagnostopoulos I., Attygalle A. D., Araujo I. B. O., Berti E., et al. (2022). The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36 (7), 1720–1748. 10.1038/s41375-022-01620-2 - DOI - PMC - PubMed
    1. Alghamdi M. A., Fallica A. N., Virzì N., Kesharwani P., Pittalà V., Greish K. (2022). The promise of nanotechnology in personalized medicine. J. Pers. Med. 12 (5), 673. 10.3390/jpm12050673 - DOI - PMC - PubMed

LinkOut - more resources